Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
Provided By GlobeNewswire
Last update: Aug 9, 2023
Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis
NEXUS Remains On Track With Top-line Results Planned for Q4 2024
Read more at globenewswire.com
